^
10d
Enrollment open • CAR T-Cell Therapy • Metastases
24d
Progress and challenges in glypican-3 targeting for hepatocellular carcinoma therapy. (PubMed, Expert Opin Ther Targets)
However, in advanced HCC, clinical trials have not demonstrated sufficient anti-tumor efficacy, in contrast with preclinical studies. Reverse translation, bedside-to-bench research, is crucial to identify the factors that have hindered GPC3 target immunotherapies.
Review • Journal • IO biomarker
|
GPC3 (Glypican 3)
30d
New P1/2 trial • CAR T-Cell Therapy • Metastases
|
GPC3 (Glypican 3)
|
cyclophosphamide • fludarabine IV
1m
The role of glypican-3 in hepatocellular carcinoma: Insights into diagnosis and therapeutic potential. (PubMed, Eur J Med Res)
GPC-3's re-expression in HCC and its involvement in key tumorigenic processes underscore its value as a biomarker for early diagnosis and a target for therapeutic intervention. Further research is warranted to fully exploit GPC-3's diagnostic and therapeutic potential in HCC management.
Review • Journal • IO biomarker
|
GPC3 (Glypican 3)
|
GPC3 expression • GPC3 overexpression
2ms
Protocol for preparing metabolically reprogrammed human CAR T cells and evaluating their in vitro effects. (PubMed, STAR Protoc)
The protocol includes producing retroviral vectors, generating CAR T cells, and conducting ecto-ADA1 activity, cytotoxicity, cell migration, and RNA sequencing assays. For complete details on the use and execution of this protocol, please refer to Hu et al.1.
Preclinical • Journal • CAR T-Cell Therapy
|
HER-2 (Human epidermal growth factor receptor 2) • GPC3 (Glypican 3) • DPP4 (Dipeptidyl Peptidase 4)
2ms
IIT trial of chimeric antigen receptor T cells targeting Glypican-3 in treatment of advance hepatocellular carcinoma (ChiCTR2400083608)
P=N/A, N=12, Not yet recruiting, The First People's Hospital of Lianyungang; The First People's Hospital of Lianyungang | Initiation date: May 2024 --> Sep 2024
Trial initiation date • CAR T-Cell Therapy
|
AFP (Alpha-fetoprotein) • GPC3 (Glypican 3)
|
GPC3 positive
2ms
New P1/2 trial • Metastases
|
AZD7003
3ms
IL-21- and CXCL9-engineered GPC3-specific CAR-T cells combined with PD-1 blockade enhance cytotoxic activities against hepatocellular carcinoma. (PubMed, Clin Exp Med)
Overall, our study successfully generated GPC3 CAR-T cells expressing both IL-21 and CXCL9, demonstrated that combining PD-1 blockade can further enhance CAR-T cell function by promoting proliferation, cytokine secretion, chemotaxis and antitumor activity. These findings present a hopeful and potentially effective strategy for GPC3-positive HCC patients.
Journal • CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker
|
CXCL9 (Chemokine (C-X-C motif) ligand 9) • GPC3 (Glypican 3) • IL21 (Interleukin 21)
3ms
Enrollment open
|
GPC3 (Glypican 3)
|
cyclophosphamide • fludarabine IV • GPC3-CAR and IL15 plus IL21
3ms
New P1 trial • CAR T-Cell Therapy
|
CT011
3ms
GPC3-targeting CART Cell in Treatment of Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
P1, N=10, Terminated, jianming xu | N=34 --> 10 | Trial completion date: Oct 2026 --> Jul 2024 | Recruiting --> Terminated; achieve the proof of concept
Enrollment change • Trial completion date • Trial termination • CAR T-Cell Therapy • Metastases
|
GPC3 (Glypican 3)
4ms
A Study of TAK-102 in Adult With Previously-Treated Solid Tumors (clinicaltrials.gov)
P1, N=11, Active, not recruiting, Takeda | Trial completion date: Dec 2026 --> Jul 2026 | Trial primary completion date: Dec 2026 --> Jul 2026
Trial completion date • Trial primary completion date
|
GPC3 (Glypican 3)
|
NIB102
4ms
rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR-T cell therapy in solid tumors. (PubMed, J Immunother Cancer)
This study provides a rationale for NT-I7 plus CAR-T cell combination therapy for solid tumors in humans.
Journal • CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker
|
PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • MSLN (Mesothelin) • CD4 (CD4 Molecule) • GPC3 (Glypican 3) • IL7 (Interleukin 7)
|
Hyleukin-7 (efineptakin alfa)
4ms
IIT trial of chimeric antigen receptor T cells in treatment of advance hepatocellular carcinoma (ChiCTR2400083608)
P=N/A, N=12, Recruiting, The First People's Hospital of Lianyungang; The First People's Hospital of Lianyungang
New trial
|
AFP (Alpha-fetoprotein) • GPC3 (Glypican 3)
4ms
LOCUS: LTFU for All Cell and Gene Therapy Studies (clinicaltrials.gov)
P=N/A, N=64, Not yet recruiting, AstraZeneca | Initiation date: Jun 2024 --> Oct 2024
Trial initiation date • Gene therapy
5ms
GPC3/Mesothelin-CAR-γδT Cells Against Cancers (clinicaltrials.gov)
P1, N=30, Recruiting, Second Affiliated Hospital of Guangzhou Medical University | Not yet recruiting --> Recruiting | Trial completion date: Dec 2033 --> Dec 2036 | Initiation date: Jan 2024 --> May 2024 | Trial primary completion date: Nov 2026 --> Nov 2030
Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date
5ms
GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers (clinicaltrials.gov)
P1, N=30, Recruiting, Second Affiliated Hospital of Guangzhou Medical University | Trial completion date: Aug 2026 --> Aug 2036 | Trial primary completion date: Aug 2024 --> Aug 2026
Trial completion date • Trial primary completion date • CAR T-Cell Therapy • IO biomarker
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18) • AXL (AXL Receptor Tyrosine Kinase) • MSLN (Mesothelin) • CD276 (CD276 Molecule) • GPC3 (Glypican 3) • TGFB1 (Transforming Growth Factor Beta 1) • GUCY2C (Guanylate Cyclase 2C) • PSCA (Prostate Stem Cell Antigen 2)
|
GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells
5ms
Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers (clinicaltrials.gov)
P1, N=30, Recruiting, Second Affiliated Hospital of Guangzhou Medical University | Trial completion date: Mar 2033 --> Mar 2036 | Trial primary completion date: Mar 2026 --> Mar 2029
Trial completion date • Trial primary completion date • CAR T-Cell Therapy • IO biomarker
|
MSLN (Mesothelin)
5ms
ZZCART-003: GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression (clinicaltrials.gov)
P1, N=30, Recruiting, Second Affiliated Hospital of Guangzhou Medical University | Trial completion date: Aug 2029 --> Aug 2036 | Trial primary completion date: Aug 2025 --> Aug 2029
Trial completion date • Trial primary completion date • CAR T-Cell Therapy • IO biomarker
|
GPC3 (Glypican 3)
|
TGFβ targeting CAR-T cells
5ms
Bispecific CAR-T cells targeting FAP and GPC3 have the potential to treat hepatocellular carcinoma. (PubMed, Mol Ther Oncol)
The anti-FAP-GPC3 bispecific CAR-T cells also exhibited superior antitumor efficacy and significantly prolonged the survival of mice compared with single-target CAR-T cells in vivo. Overall, the use of anti-FAP-GPC3 bispecific CAR-T cells is a promising treatment approach to reduce tumor recurrence caused by tumor antigen heterogeneity.
Journal • CAR T-Cell Therapy • IO biomarker
|
GPC3 (Glypican 3) • FAP (Fibroblast activation protein, alpha)
5ms
GPC3-targeted CAR-M cells exhibit potent antitumor activity against hepatocellular carcinoma. (PubMed, Biochem Biophys Rep)
In 3D NACs-origami spheroid model of HCC, CAR-Ms were further demonstrated to have a significant tumor killing effect. Together, our study provides a new strategy for the treatment of HCC through CAR-M cells targeting GPC3, which provides a basis for the research and treatment of hepatocellular carcinoma.
Journal
|
GPC3 (Glypican 3)
5ms
New P1 trial • CAR T-Cell Therapy • Metastases
5ms
Moderate expression of CD39 in GPC3-CAR-T cells shows high efficacy against hepatocellular carcinoma. (PubMed, Front Med)
The combination of mdivi-1 and CD39 knockdown in CAR-T cells yielded the highest proportion of infiltrated CD39int CAR-T cells and demonstrated a robust antitumor activity in vivo. In conclusion, this study revealed the crucial role of CD39 in CAR-T cell function, demonstrated the potential therapeutic efficacy of combining mdivi-1 with CD39 knockdown in HCC, and provided a novel treatment strategy for HCC patients in the field of cellular immunotherapy.
Journal • CAR T-Cell Therapy • IO biomarker
|
CD8 (cluster of differentiation 8) • GPC3 (Glypican 3) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)
6ms
Expand available targets for CAR-T therapy to overcome tumor drug resistance based on the "Evolutionary Traps". (PubMed, Pharmacol Res)
In this study, lapatinib-resistant cells were used to test the concept of "Evolutionary Traps" and no suitable target stand out because of the identified genes without accessible drug...To test whether this concept is cell line or drug dependent, we analyzed 21 drug-resistant tumor cell expression profiles reveal that JAG1, GPC3, and L1CAM, which are suitable targets for CAR-T treatment, are significantly upregulated in various drug-resistant tumor cells. Our findings shed light on the feasibility of utilizing CAR-T therapy to treat drug-resistant tumors and broaden the concept of the "Evolutionary Trap".
Journal • IO biomarker
|
GPC3 (Glypican 3) • JAG1 (Jagged Canonical Notch Ligand 1) • L1CAM (L1 cell adhesion molecule)
|
lapatinib
6ms
GPC3-targeted CAR-T cells expressing GLUT1 or AGK exhibit enhanced antitumor activity against hepatocellular carcinoma. (PubMed, Acta Pharmacol Sin)
Finally, we revealed that GLUT1 or AGK maintained anti-apoptosis ability in CD8+ T cells via activation of the PI3K/Akt pathway. This finding might identify a therapeutic strategy for advanced HCC.
Journal • CAR T-Cell Therapy • IO biomarker
|
CD8 (cluster of differentiation 8) • GPC3 (Glypican 3) • AGK (Acylglycerol Kinase) • SLC2A1 (Solute Carrier Family 2 Member 1)
|
GPC3 positive
6ms
IM83 Clinical Study of CAR-T Cell Therapy in Patients With Relapsed or Refractory Osteosarcoma (clinicaltrials.gov)
P1, N=9, Not yet recruiting, Beijing Immunochina Medical Science & Technology Co., Ltd.
New P1 trial • CAR T-Cell Therapy
|
cyclophosphamide • IM83
8ms
LOCUS: LTFU for All Cell and Gene Therapy Studies (clinicaltrials.gov)
P=N/A, N=64, Not yet recruiting, AstraZeneca | N=30 --> 64 | Initiation date: Feb 2024 --> Jun 2024
Enrollment change • Trial initiation date • Gene therapy
8ms
To Evaluate the Safety, Tolerability and Preliminary Efficacy of EU307 (clinicaltrials.gov)
P1, N=12, Recruiting, Eutilex | Not yet recruiting --> Recruiting | Trial completion date: Nov 2024 --> Dec 2025 | Trial primary completion date: May 2024 --> Jun 2025
Enrollment open • Trial completion date • Trial primary completion date • CAR T-Cell Therapy • Metastases
|
IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • GPC3 (Glypican 3) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • IL18 (Interleukin 18)
|
EU307
9ms
Enrollment change
|
GPC3 (Glypican 3)
|
GPC3 expression
|
Lenvima (lenvatinib) • AZD7003
10ms
New P1 trial • CAR T-Cell Therapy
|
GPC3-CAR and IL15 plus IL21
10ms
BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors (clinicaltrials.gov)
P1/2, N=110, Recruiting, Sotio Biotech Inc. | Trial completion date: Jul 2039 --> Dec 2041 | Trial primary completion date: Jul 2024 --> Apr 2026
Trial completion date • Trial primary completion date • Metastases
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • BRCA (Breast cancer early onset) • GPC3 (Glypican 3)
|
EGFR mutation • ALK translocation • BRCA mutation • GPC3 expression • GPC3 overexpression
|
cyclophosphamide • BOXR1030
10ms
New trial • Gene therapy
11ms
A Study of TAK-102 in Adult With Previously-Treated Solid Tumors (clinicaltrials.gov)
P1, N=11, Active, not recruiting, Takeda | Recruiting --> Active, not recruiting | N=18 --> 11
Enrollment closed • Enrollment change
|
GPC3 (Glypican 3)
|
GPC3 expression
|
NIB102
11ms
B010-A Injection for Treating Patients With GPC3 Positive Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
P1, N=3, Active, not recruiting, Tongji University | Recruiting --> Active, not recruiting | Trial completion date: Sep 2022 --> Sep 2024 | Trial primary completion date: Aug 2022 --> Aug 2024
Enrollment closed • Trial completion date • Trial primary completion date • Metastases
|
GPC3 (Glypican 3)
|
GPC3 positive
|
B010-A
11ms
Enrollment open • CAR T-Cell Therapy • Metastases
|
GPC3 (Glypican 3)
|
GPC3 positive
|
cyclophosphamide
12ms
GPC3-IL7-CCL19-CAR-T primes immune microenvironment reconstitution for hepatocellular carcinoma therapy. (PubMed, Cell Biol Toxicol)
In conclusion, GPC3-7-19-CAR-T cells achieved antitumor effects superior to those of conventional GPC3-CAR-T cells by reconstructing the TME induced by the dominant CD4 T and CD8 T cell subsets. Most importantly, GPC3-7-19-CAR-T cells exhibited good safety and antitumor efficacy in HCC patients in the clinic. ► Novel GPC3-7-19-CAR-T cells designed with mediate level of IL-7 secretion and high level of CCL19 secretion, which could recruit more mature DCs to assist killing on GPC3HCCs. ►DC cells recruited by CCL19 could interact with CD4 T cells and promote the differentiation of CD4T cells into CD4T and CD8T subsets, leading a better anti-tumor effect on GPC3HCCs. ►Compared with conventional GPC3-CAR-T, GPC3-7-CCL19-CAR-T cells could reverse tumor immunosuppressive microenvironment by reducing PMN-MDSC and Treg cell infiltration.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • GPC3 (Glypican 3) • CCL19 (C-C Motif Chemokine Ligand 19) • IL7 (Interleukin 7)
12ms
New P1 trial • CAR T-Cell Therapy • Metastases
|
cyclophosphamide • ECT204
1year
New P1/2 trial • CAR T-Cell Therapy • Metastases
|
GPC3 (Glypican 3)
|
GPC3 positive
|
cyclophosphamide
1year
GLYPICAN-3 PROTEIN QUANTITATION AND CELLULAR LOCALIZATION IN PEDIATRIC LIVER TUMORS (AASLD 2023)
GPC3 protein is expressed in a large percentage of HB and FLC tumors, but with variable intensity and distribution. Characterization of GPC3 tumor protein H-score and pattern of immunoreactivity are two independent parameters that may be helpful to quantitate GPC3 immunostaining of tumor and correlate with treatment response to a variety of GPC3 targeted therapeutics.
Clinical • IO biomarker
|
GPC3 (Glypican 3)
|
GPC3 expression • CTNNB1 expression • GPC3 positive
1year
Engineered human IL-2/IL-2Rß orthogonal pairs selectively enhance anti-GPC3 CAR T cells in vivo to drive complete responses in solid epithelial tumor models (SITC 2023)
Importantly, STK-009 induced the expression of cytotoxic machinery, pro-survival, and proliferative genes in tumor-infiltrating SYNCAR-002 (figure 3). Conclusions These findings validate that the orthogonal IL-2 platform has the potential to improve the efficacy and durability of CAR T therapy for solid tumor targets such as GPC3 by selectively expanding CAR-T cells in vivo and activating CAR-T cells in a hostile tumor microenvironment.
Preclinical • CAR T-Cell Therapy • IO biomarker
|
CD19 (CD19 Molecule) • GPC3 (Glypican 3) • IL2 (Interleukin 2)
|
CD19 expression • GPC3 expression
|
STK-009/SYNCAR-001
1year
RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: a phase I trial. (PubMed, EClinicalMedicine)
CT017 CAR T cells were engineered to co-express CAR-GPC3 and runt-related transcription factor 3 (RUNX3), which triggers CD8 T-cell infiltration into the cancer microenvironment...These results need to be confirmed in a robust clinical trial. This study was funded by CARsgen Therapeutics Co., Ltd.
P1 data • Journal • CAR T-Cell Therapy • Metastases
|
CD8 (cluster of differentiation 8) • GPC3 (Glypican 3) • TCF3 (Transcription Factor 3) • RUNX3 (RUNX Family Transcription Factor 3)
|
GPC3 expression • GPC3 positive
|
CT017 • CT0180
over1year
CT0180-CG1203: Phase I Clinical Trial of CT0180 Cells in the Treatment of Hepatocellular Carcinoma (clinicaltrials.gov)
P1, N=21, Recruiting, Zhejiang University | Trial completion date: Apr 2023 --> Jun 2024 | Trial primary completion date: Mar 2023 --> Jun 2024
Trial completion date • Trial primary completion date • Metastases
|
PD-L1 (Programmed death ligand 1) • GPC3 (Glypican 3)
|
cyclophosphamide • CT0180